1
|
Šachlevičiūtė U, Gonzalez G, Kvasnicová M, Štěpánková Š, Kleizienė N, Bieliauskas A, Zatloukal M, Strnad M, Sløk FA, Kvasnica M, Šačkus A, Žukauskaitė A. Synthesis and neuroprotective activity of 3-aryl-3-azetidinyl acetic acid methyl ester derivatives. Arch Pharm (Weinheim) 2023; 356:e2300378. [PMID: 37797174 DOI: 10.1002/ardp.202300378] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2023] [Revised: 09/14/2023] [Accepted: 09/15/2023] [Indexed: 10/07/2023]
Abstract
A library of 3-aryl-3-azetidinyl acetic acid methyl ester derivatives was prepared from N-Boc-3-azetidinone employing the Horner-Wadsworth-Emmons reaction, rhodium(I)-catalyzed conjugate addition of arylboronic acids, and subsequent elaborations to obtain N-unprotected hydrochlorides, N-alkylated and N-acylated azetidine derivatives. The compounds were evaluated for acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) inhibitory activity, revealing several derivatives to possess AChE inhibition comparable to that of the AChE inhibitor rivastigmine. The binding mode of the AChE inhibitor donepezil and selected active compounds 26 and 27 within the active site of AChE was studied using molecular docking. Furthermore, the neuroprotective activity of the prepared compounds was evaluated in models associated with Parkinson's disease (salsolinol-induced) and aspects of Alzheimer's disease (glutamate-induced oxidative damage). Compound 28 showed the highest neuroprotective effect in both salsolinol- and glutamate-induced neurodegeneration models, and its protective effect in the glutamate model was revealed to be driven by a reduction in oxidative stress and caspase-3/7 activity.
Collapse
Affiliation(s)
- Urtė Šachlevičiūtė
- Institute of Synthetic Chemistry, Kaunas University of Technology, Kaunas, Lithuania
| | - Gabriel Gonzalez
- Department of Experimental Biology, Faculty of Science, Palacký University Olomouc, Olomouc, Czech Republic
- Department of Neurology, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacký University Olomouc, Olomouc, Czech Republic
| | - Marie Kvasnicová
- Department of Experimental Biology, Faculty of Science, Palacký University Olomouc, Olomouc, Czech Republic
| | - Šárka Štěpánková
- Department of Biological and Biochemical Sciences, Faculty of Chemical Technology, University of Pardubice, Pardubice, Czech Republic
| | - Neringa Kleizienė
- Institute of Synthetic Chemistry, Kaunas University of Technology, Kaunas, Lithuania
| | - Aurimas Bieliauskas
- Institute of Synthetic Chemistry, Kaunas University of Technology, Kaunas, Lithuania
| | - Marek Zatloukal
- Department of Chemical Biology, Faculty of Science, Palacký University, Olomouc, Czech Republic
| | - Miroslav Strnad
- Laboratory of Growth Regulators, Institute of Experimental Botany of the Czech Academy of Sciences & Palacký University, Olomouc, Czech Republic
| | | | - Miroslav Kvasnica
- Laboratory of Growth Regulators, Institute of Experimental Botany of the Czech Academy of Sciences & Palacký University, Olomouc, Czech Republic
| | - Algirdas Šačkus
- Institute of Synthetic Chemistry, Kaunas University of Technology, Kaunas, Lithuania
| | - Asta Žukauskaitė
- Department of Chemical Biology, Faculty of Science, Palacký University, Olomouc, Czech Republic
| |
Collapse
|
2
|
de Jesus R, Hiesinger K, van Gemmeren M. Preparative Scale Applications of C-H Activation in Medicinal Chemistry. Angew Chem Int Ed Engl 2023; 62:e202306659. [PMID: 37283078 DOI: 10.1002/anie.202306659] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2023] [Revised: 06/06/2023] [Accepted: 06/07/2023] [Indexed: 06/08/2023]
Abstract
C-H activation is an attractive methodology to increase molecular complexity without requiring substrate prefunctionalization. In contrast to well-established cross-coupling methods, C-H activation is less explored on large scales and its use in the production of pharmaceuticals faces substantial hurdles. However, the inherent advantages, such as shorter synthetic routes and simpler starting materials, motivate medicinal chemists and process chemists to overcome these challenges, and exploit C-H activation steps for the synthesis of pharmaceutically relevant compounds. In this review, we will cover examples of drugs/drug candidates where C-H activation has been implemented on a preparative synthetic scale (range between 355 mg and 130 kg). The optimization processes will be described, and each example will be examined in terms of its advantages and disadvantages, providing the reader with an in-depth understanding of the challenges and potential of C-H activation methodologies in the production of pharmaceuticals.
Collapse
Affiliation(s)
- Rita de Jesus
- Otto-Diels-Institut für Organische Chemie, Christian-Albrechts-Universität zu Kiel, Otto-Hahn-Platz 4, 24118, Kiel, Germany
| | - Kerstin Hiesinger
- Otto-Diels-Institut für Organische Chemie, Christian-Albrechts-Universität zu Kiel, Otto-Hahn-Platz 4, 24118, Kiel, Germany
| | - Manuel van Gemmeren
- Otto-Diels-Institut für Organische Chemie, Christian-Albrechts-Universität zu Kiel, Otto-Hahn-Platz 4, 24118, Kiel, Germany
| |
Collapse
|
3
|
Messire G, Ferreira V, Caillet E, Bodin L, Auville A, Berteina-Raboin S. Sabinene: A New Green Solvent Used in the Synthesis of Thiazolo[5,4- b]pyridines by Thermal or Microwave Activation. Molecules 2023; 28:6924. [PMID: 37836766 PMCID: PMC10574264 DOI: 10.3390/molecules28196924] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2023] [Revised: 09/29/2023] [Accepted: 10/02/2023] [Indexed: 10/15/2023] Open
Abstract
Following the work already carried out in our laboratory on eucalyptol, a new green solvent derived from biomass, we are now looking at sabinene as another new green solvent. Sabinene is also derived from biomass, has no known toxicity and can be recycled by distillation. We have shown that it can be used as it is or distilled to synthesize thiazolo[5,4-b]pyridine heterocycles by thermal activation or microwave irradiation. This new solvent was compared with various conventional and green solvents. The conditions were optimised to enable us to carry out the syntheses in satisfactory yields, and we were able to show that sabinene, a natural bicyclic monoterpene, could be used effectively as a solvent.
Collapse
Affiliation(s)
| | | | | | | | | | - Sabine Berteina-Raboin
- Institut de Chimie Organique et Analytique (ICOA), Université d’Orléans, UMR-CNRS 7311, BP 6759, rue de Chartres, 45067 Orléans, France; (G.M.); (V.F.); (E.C.); (L.B.); (A.A.)
| |
Collapse
|
4
|
Zhao H, Brånalt J, Perry M, Tyrchan C. The Role of Allylic Strain for Conformational Control in Medicinal Chemistry. J Med Chem 2023. [PMID: 37285219 DOI: 10.1021/acs.jmedchem.3c00446] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/09/2023]
Abstract
It is axiomatic in medicinal chemistry that optimization of the potency of a small molecule at a macromolecular target requires complementarity between the ligand and target. In order to minimize the conformational penalty on binding, both enthalpically and entropically, it is therefore preferred to have the ligand preorganized in the bound conformation. In this Perspective, we highlight the role of allylic strain in controlling conformational preferences. Allylic strain was originally described for carbon-based allylic systems, but the same principles apply to other types of structure with sp2 or pseudo-sp2 arrangements. These systems include benzylic (including heteroaryl methyl) positions, amides, N-aryl groups, aryl ethers, and nucleotides. We have derived torsion profiles from small molecule X-ray structures for these systems. Through multiple examples, we show how these effects have been applied in drug discovery and how they can be used prospectively to influence conformation in the design process.
Collapse
Affiliation(s)
- Hongtao Zhao
- Medicinal Chemistry, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg 43183, Sweden
| | - Jonas Brånalt
- Medicinal Chemistry, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg 43183, Sweden
| | - Matthew Perry
- Medicinal Chemistry, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg 43183, Sweden
| | - Christian Tyrchan
- Medicinal Chemistry, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg 43183, Sweden
| |
Collapse
|
5
|
Li MF, Chen LQ, Wang JY, Tu MS, Hao WJ, Jiang B. Lewis Acid-Catalyzed Remote Site-Selective Ring Deconstruction of Cyclobuteno[ a]naphthalene-4-ones to Access Unsymmetric 1,1-Diarylated Olefins. J Org Chem 2023; 88:3615-3625. [PMID: 36855323 DOI: 10.1021/acs.joc.2c02804] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/02/2023]
Abstract
A catalytic site-selective ring deconstruction of cyclobuteno[a]naphthalene-4-ones with alcohols is reported, enabling the direct production of a wide range of unsymmetric 1,1-diarylated olefins with good yields and complete regioselectivity. The late-stage application of these resulting terminal olefins demonstrates great possibilities to apply this strategy to complex molecules. The protocol features good functional group compatibility, broad substrate scope, and controllable site selectivity.
Collapse
Affiliation(s)
- Meng-Fan Li
- School of Chemistry & Materials Science, Jiangsu Key Laboratory of Green Synthetic Chemistry for Functional Materials, Jiangsu Normal University, Xuzhou 221116, China
| | - Ling-Qi Chen
- School of Chemistry & Materials Science, Jiangsu Key Laboratory of Green Synthetic Chemistry for Functional Materials, Jiangsu Normal University, Xuzhou 221116, China
| | - Jia-Yin Wang
- School of Chemistry & Materials Science, Jiangsu Key Laboratory of Green Synthetic Chemistry for Functional Materials, Jiangsu Normal University, Xuzhou 221116, China
| | - Man-Su Tu
- School of Chemistry & Materials Science, Jiangsu Key Laboratory of Green Synthetic Chemistry for Functional Materials, Jiangsu Normal University, Xuzhou 221116, China
| | - Wen-Juan Hao
- School of Chemistry & Materials Science, Jiangsu Key Laboratory of Green Synthetic Chemistry for Functional Materials, Jiangsu Normal University, Xuzhou 221116, China
| | - Bo Jiang
- School of Chemistry & Materials Science, Jiangsu Key Laboratory of Green Synthetic Chemistry for Functional Materials, Jiangsu Normal University, Xuzhou 221116, China
| |
Collapse
|
6
|
Nazir MS, Nawaz A, Aslam S, Ahmad M, Zahoor AF, Mohsin NUA. Synthetic strategies for thiazolopyridine derivatives. SYNTHETIC COMMUN 2023. [DOI: 10.1080/00397911.2023.2183363] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/06/2023]
Affiliation(s)
| | - Anam Nawaz
- Department of Chemistry, Government College University, Faisalabad, Pakistan
| | - Sana Aslam
- Department of Chemistry, Government College Women University, Faisalabad, Pakistan
| | - Matloob Ahmad
- Department of Chemistry, Government College University, Faisalabad, Pakistan
| | - Ameer Fawad Zahoor
- Department of Chemistry, Government College University, Faisalabad, Pakistan
| | - Noor ul Amin Mohsin
- Department of Pharmaceutical Chemistry, Faculty of Pharmaceutical Sciences, Government College University, Faisalabad, Pakistan
| |
Collapse
|
7
|
Design, Synthesis and Biological Evaluation of Arylpyridin-2-yl Guanidine Derivatives and Cyclic Mimetics as Novel MSK1 Inhibitors. An Application in an Asthma Model. Molecules 2021; 26:molecules26020391. [PMID: 33450992 PMCID: PMC7828447 DOI: 10.3390/molecules26020391] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2020] [Revised: 01/08/2021] [Accepted: 01/11/2021] [Indexed: 01/23/2023] Open
Abstract
Mitogen- and Stress-Activated Kinase 1 (MSK1) is a nuclear kinase, taking part in the activation pathway of the pro-inflammatory transcription factor NF-kB and is demonstrating a therapeutic target potential in inflammatory diseases such as asthma, psoriasis and atherosclerosis. To date, few MSK1 inhibitors were reported. In order to identify new MSK1 inhibitors, a screening of a library of low molecular weight compounds was performed, and the results highlighted the 6-phenylpyridin-2-yl guanidine (compound 1a, IC50~18 µM) as a starting hit for structure-activity relationship study. Derivatives, homologues and rigid mimetics of 1a were designed, and all synthesized compounds were evaluated for their inhibitory activity towards MSK1. Among them, the non-cytotoxic 2-aminobenzimidazole 49d was the most potent at inhibiting significantly: (i) MSK1 activity, (ii) the release of IL-6 in inflammatory conditions in vitro (IC50~2 µM) and (iii) the inflammatory cell recruitment to the airways in a mouse model of asthma.
Collapse
|
8
|
Identification of Novel Thiazolo[5,4- b]Pyridine Derivatives as Potent Phosphoinositide 3-Kinase Inhibitors. Molecules 2020; 25:molecules25204630. [PMID: 33053730 PMCID: PMC7594053 DOI: 10.3390/molecules25204630] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2020] [Revised: 09/29/2020] [Accepted: 10/01/2020] [Indexed: 11/25/2022] Open
Abstract
A series of novel 2-pyridyl, 4-morpholinyl substituted thiazolo[5,4-b]pyridine analogues have been designed and synthesized in this paper. These thiazolo[5,4-b]pyridines were efficiently prepared in seven steps from commercially available substances in moderate to good yields. All of these N-heterocyclic compounds were characterized by nuclear magnetic resonance (NMR) and high-resolution mass spectrometry (HRMS) analysis and tested for phosphoinositide 3-kinase (PI3K) enzymatic assay. The results indicated that these N-heterocyclic compounds showed potent PI3K inhibitory activity, and the IC50 of a representative compound (19a) could reach to 3.6 nm. The structure−activity relationships (SAR) study showed that sulfonamide functionality was important for PI3Kα inhibitory activity, and 2-chloro-4-florophenyl sulfonamide (19b), or 5-chlorothiophene-2-sulfonamide (19c) showed potent inhibitory activity with a nanomolar IC50 value. The pyridyl attached to thiazolo[5,4-b]pyridine was another key structural unit for PI3Kα inhibitory potency, and replacement by phenyl lead to a significant decrease in activity. Enzymatic Inhibition results showed that compound 19a inhibited PI3Kα, PI3Kγ, or PI3Kδ with a nanomolar IC50 value, but its inhibitory activity on PI3Kβ was approximately 10-fold reduced. Further docking analysis revealed that the N-heterocyclic core of compound 19a was directly involved in the binding to the kinase through the key hydrogen bonds interaction.
Collapse
|
9
|
Langeslag M, Kress M. The ceramide-S1P pathway as a druggable target to alleviate peripheral neuropathic pain. Expert Opin Ther Targets 2020; 24:869-884. [PMID: 32589067 DOI: 10.1080/14728222.2020.1787989] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
Introduction: Neuropathic pain disorders are diverse, and the currently available therapies are ineffective in the majority of cases. Therefore, there is a major need for gaining novel mechanistic insights and developing new treatment strategies for neuropathic pain. Areas covered: We performed an in-depth literature search on the molecular mechanisms and systemic importance of the ceramide-to-S1P rheostat regulating neuron function and neuroimmune interactions in the development of neuropathic pain. Expert opinion: The S1P receptor modulator FTY720 (fingolimod, Gilenya®), LPA receptor antagonists and several mechanistically related compounds in clinical development raise great expectations for treating neuropathic pain disorders. Research on S1P receptors, S1P receptor modulators or SPHK inhibitors with distinct selectivity, pharmacokinetics and safety must provide more mechanistic insight into whether they may qualify as useful treatment options for neuropathic pain disorders. The functional relevance of genetic variations within the ceramide-to-S1P rheostat should be explored for an enhanced understanding of neuropathic pain pathogenesis. The ceramide-to-S1P rheostat is emerging as a critically important regulator hub of neuroimmune interactions along the pain pathway, and improved mechanistic insight is required to develop more precise and effective drug treatment options for patients suffering from neuropathic pain disorders.
Collapse
Affiliation(s)
- Michiel Langeslag
- Institute of Physiology, DPMP, Medical University Innsbruck , Austria
| | - Michaela Kress
- Institute of Physiology, DPMP, Medical University Innsbruck , Austria
| |
Collapse
|
10
|
Caille S, Cui S, Faul MM, Mennen SM, Tedrow JS, Walker SD. Molecular Complexity as a Driver for Chemical Process Innovation in the Pharmaceutical Industry. J Org Chem 2019; 84:4583-4603. [DOI: 10.1021/acs.joc.9b00735] [Citation(s) in RCA: 34] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Affiliation(s)
- Seb Caille
- Process Development, Amgen, Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Sheng Cui
- Process Development, Amgen, Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
| | - Margaret M. Faul
- Process Development, Amgen, Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Steven M. Mennen
- Process Development, Amgen, Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
| | - Jason S. Tedrow
- Process Development, Amgen, Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
| | - Shawn D. Walker
- Process Development, Amgen, Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
| |
Collapse
|
11
|
Marciniak A, Camp SM, Garcia JGN, Polt R. An update on sphingosine-1-phosphate receptor 1 modulators. Bioorg Med Chem Lett 2018; 28:3585-3591. [PMID: 30409535 DOI: 10.1016/j.bmcl.2018.10.042] [Citation(s) in RCA: 20] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2018] [Revised: 10/22/2018] [Accepted: 10/25/2018] [Indexed: 12/14/2022]
Abstract
Sphingolipids represent an essential class of lipids found in all eukaryotes, and strongly influence cellular signal transduction. Autoimmune diseases like asthma and multiple sclerosis (MS) are mediated by the sphingosine-1-phosphate receptor 1 (S1P1) to express a variety of symptoms and disease patterns. Inspired by its natural substrate, an array of artificial sphingolipid derivatives has been developed to target this specific G protein-coupled receptor (GPCR) in an attempt to suppress autoimmune disorders. FTY720, also known as fingolimod, is the first oral disease-modifying therapy for MS on the market. In pursuit of improved stability, bioavailability, and efficiency, structural analogues of this initial prodrug have emerged over time. This review covers a brief introduction to the sphingolipid metabolism, the mechanism of action on S1P1, and an updated overview of synthetic sphingosine S1P1 agonists.
Collapse
Affiliation(s)
- Alexander Marciniak
- Department of Chemistry & Biochemistry, The University of Arizona, Tucson, AZ 85721, United States.
| | - Sara M Camp
- Department of Medicine, The University of Arizona, Tucson, AZ 85724, United States.
| | - Joe G N Garcia
- Department of Medicine, The University of Arizona, Tucson, AZ 85724, United States.
| | - Robin Polt
- Department of Chemistry & Biochemistry, The University of Arizona, Tucson, AZ 85721, United States.
| |
Collapse
|
12
|
Identification and Structure-Activity Relationship (SAR) of potent and selective oxadiazole-based agonists of sphingosine-1-phosphate receptor (S1P 1). Bioorg Chem 2018; 82:41-57. [PMID: 30268973 DOI: 10.1016/j.bioorg.2018.09.008] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2018] [Revised: 08/31/2018] [Accepted: 09/07/2018] [Indexed: 12/23/2022]
Abstract
Agonism of S1P1 receptor has been proven to be responsible for peripheral blood lymphopenia and elicts the identification of various S1P1 modulators. In this paper we described a series of oxadiazole-based S1P1 direct-acting agonists disubstituted on terminal benzene ring, with high potency for S1P1 receptor and favorable selectivity against S1P3 receptor. In addition, two representative agents named 16-3b and 16-3g demonstrated impressive efficacy in lymphocyte reduction along with reduced effect on heart rate when orally administered. Furthermore, these compounds have been shown to possess desired pharmacokinetic (PK) and physicochemical profiles. The binding mode between 16-3b and the activated S1P1 model was also studied.
Collapse
|
13
|
Stoit AR, Lange JH, Coolen HK, Rensink A, van den Hoogenband A, den Hartog AP, van Schaik S, Kruse CG. Spiro-1-benzofuranpiperidinylalkanoic acids as a novel and selective sphingosine S1P5 receptor agonist chemotype. Bioorg Med Chem Lett 2018; 28:459-465. [DOI: 10.1016/j.bmcl.2017.12.018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2017] [Accepted: 12/08/2017] [Indexed: 10/18/2022]
|
14
|
Kurata H, Kusumi K, Otsuki K, Suzuki R, Kurono M, Komiya T, Hagiya H, Mizuno H, Shioya H, Ono T, Takada Y, Maeda T, Matsunaga N, Kondo T, Tominaga S, Nunoya KI, Kiyoshi H, Komeno M, Nakade S, Habashita H. Discovery of a 1-Methyl-3,4-dihydronaphthalene-Based Sphingosine-1-Phosphate (S1P) Receptor Agonist Ceralifimod (ONO-4641). A S1P1 and S1P5 Selective Agonist for the Treatment of Autoimmune Diseases. J Med Chem 2017; 60:9508-9530. [DOI: 10.1021/acs.jmedchem.7b00785] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Affiliation(s)
- Haruto Kurata
- Medicinal
Chemistry Research Laboratories, Ono Pharmaceutical Co., Ltd., 3-1-1 Sakurai, Shimamoto, Mishima, Osaka 618-8585, Japan
| | - Kensuke Kusumi
- Medicinal
Chemistry Research Laboratories, Ono Pharmaceutical Co., Ltd., 3-1-1 Sakurai, Shimamoto, Mishima, Osaka 618-8585, Japan
| | - Kazuhiro Otsuki
- Medicinal
Chemistry Research Laboratories, Ono Pharmaceutical Co., Ltd., 3-1-1 Sakurai, Shimamoto, Mishima, Osaka 618-8585, Japan
| | - Ryo Suzuki
- Medicinal
Chemistry Research Laboratories, Ono Pharmaceutical Co., Ltd., 3-1-1 Sakurai, Shimamoto, Mishima, Osaka 618-8585, Japan
| | - Masakuni Kurono
- Medicinal
Chemistry Research Laboratories, Ono Pharmaceutical Co., Ltd., 3-1-1 Sakurai, Shimamoto, Mishima, Osaka 618-8585, Japan
| | | | | | | | | | | | | | | | | | | | | | | | - Hidekazu Kiyoshi
- Safety
Research Laboratories, Ono Pharmaceutical Co., Ltd., 50-10 Yamagishi, Mikuni, Sakai, Fukui 913-8538, Japan
| | - Masaharu Komeno
- Safety
Research Laboratories, Ono Pharmaceutical Co., Ltd., 50-10 Yamagishi, Mikuni, Sakai, Fukui 913-8538, Japan
| | | | - Hiromu Habashita
- Medicinal
Chemistry Research Laboratories, Ono Pharmaceutical Co., Ltd., 3-1-1 Sakurai, Shimamoto, Mishima, Osaka 618-8585, Japan
| |
Collapse
|
15
|
Dyckman AJ. Modulators of Sphingosine-1-phosphate Pathway Biology: Recent Advances of Sphingosine-1-phosphate Receptor 1 (S1P 1) Agonists and Future Perspectives. J Med Chem 2017; 60:5267-5289. [PMID: 28291340 DOI: 10.1021/acs.jmedchem.6b01575] [Citation(s) in RCA: 41] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
The sphingoid base derived class of lipids (sphingolipids) is a family of interconverting molecules that play key roles in numerous structural and signaling processes. The biosynthetic pathway of the sphingolipids affords many opportunities for therapeutic intervention: targeting the ligands directly, targeting the various proteins involved in the interconversion of the ligands, or targeting the receptors that respond to the ligands. The focus of this article is on the most advanced of the sphingosine-related therapeutics, agonists of sphingosine-1-phosphate receptor 1 (S1P1). The diverse structural classes of S1P1 agonists will be discussed and the status of compounds of clinical relevance will be detailed. An examination of how potential safety concerns are being navigated with compounds currently under clinical evaluation is followed by a discussion of the novel methods being explored to identify next-generation S1P1 agonists with improved safety profiles. Finally, therapeutic opportunities for sphingosine-related targets outside of S1P1 are touched upon.
Collapse
Affiliation(s)
- Alaric J Dyckman
- Research and Development, Bristol-Myers Squibb Company , P.O. Box 4000, Princeton, New Jersey 08543-4000, United States
| |
Collapse
|
16
|
Ke S. Convenient Structural Diversity‐Guided Synthesis of Functionalized Sulfur‐Containing Heterocycles
via
α‐Substituted Cyanoacetamides. J Heterocycl Chem 2016. [DOI: 10.1002/jhet.2792] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- Shaoyong Ke
- National Biopesticide Engineering Research Center, Hubei Biopesticide Engineering Research CenterHubei Academy of Agricultural Sciences Wuhan 430064 People's Republic of China
| |
Collapse
|
17
|
Wu DZ, Zhi YG. An efficient method for the construction of 2-Aminothiazolo[5,4-c]pyridines via K3[Fe(CN)6] oxidized SP2 CH Functionalization. Tetrahedron 2016. [DOI: 10.1016/j.tet.2016.11.032] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
18
|
Shen B, Semin D, Fang J, Guo G. Analysis of 4-bromo-3-fluorobenzaldehyde and separation of its regioisomers by one-dimensional and two-dimensional gas chromatography. J Chromatogr A 2016; 1462:115-23. [PMID: 27492600 DOI: 10.1016/j.chroma.2016.07.071] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2016] [Revised: 07/25/2016] [Accepted: 07/26/2016] [Indexed: 10/21/2022]
Abstract
A starting material, 4-bromo-3-fluorobenzaldehyde, was used for active drug substance (API) AMG 369 production. The presence of the regioisomer impurities in the starting material 4-bromo-3-fluorobenzaldehyde presented significant challenges for the API synthetic route development due to the physical-chemical similarities of the impurities. These impurities significantly impact on the purity of the starting-material and final drug substance. Control of these impurities is important due to the potential genotoxicity of these impurities (p-GTI). Analytical development was carried out to develop GC methods with high resolving power and high sensitivity to quantify the regioisomers presented in starting material and therefore to control the purity of the starting material and the final drug substance. In the study, complete resolution of the ten regioisomers by 1D-GC and heart-cutting two-dimensional GC (2D-GC) was achieved. A sensitive GC/micro electron capture detection (μ-ECD) method with high resolving power and sensitivity to fully resolve all the ten regioisomers of 4-bromo-3-fluorobenzaldehyde was obtained by using a CHIRALDEX GC column (1D- GC). To facilitate the systematic GC method development, heart-cutting two-dimensional gas chromatography (2D-GC) using a Deans switch was exploited for the separation of the ten regioisomers. The resulting heart-cutting 2D-GC method successfully separated all the ten regioisomers with better sensitivity and resolution. Regioisomer impurities in the starting material were identified and quantified by these GC methods. The sensitivity for the methods is in the range of 0.004ng to 0.02ng for the regioisomers. Linearity for the methods is: R(2)=0.999 to 1.000. The methods were suitable for control of the regioisomer impurities, p-GTIs, in the starting material and final drug substance.
Collapse
Affiliation(s)
- Bo Shen
- Attribute Sciences, Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91320, USA.
| | - David Semin
- Attribute Sciences, Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91320, USA
| | - Jan Fang
- Quality & Regulatory Management, LLC, 2629 Townsgate Rd, Westlake Village, CA 91361, USA
| | - Gary Guo
- Commercial Analytical Operation, Gilead Sciences, 333 Lakeside Drive Foster City, CA 94404, USA
| |
Collapse
|
19
|
Vogt D, Stark H. Therapeutic Strategies and Pharmacological Tools Influencing S1P Signaling and Metabolism. Med Res Rev 2016; 37:3-51. [PMID: 27480072 DOI: 10.1002/med.21402] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2016] [Revised: 06/01/2016] [Accepted: 06/28/2016] [Indexed: 02/06/2023]
Abstract
During the last two decades the study of the sphingolipid anabolic, catabolic, and signaling pathways has attracted enormous interest. Especially the introduction of fingolimod into market as first p.o. therapeutic for the treatment of multiple sclerosis has boosted this effect. Although the complex regulation of sphingosine-1-phosphate (S1P) and other catabolic and anabolic sphingosine-related compounds is not fully understood, the influence on different (patho)physiological states from inflammation to cytotoxicity as well as the availability of versatile pharmacological tools that represent new approaches to study these states are described. Here, we have summarized various aspects concerning the many faces of sphingolipid function modulation by different pharmacological tools up to clinical candidates. Due to the immense heterogeneity of physiological or pharmacological actions and complex cross regulations, it is difficult to predict their role in upcoming therapeutic approaches. Currently, inflammatory, immunological, and/or antitumor aspects are discussed.
Collapse
Affiliation(s)
- Dominik Vogt
- Institute of Pharmaceutical Chemistry, Goethe University Frankfurt, Max-von-Laue-Straße 9, D-60438, Frankfurt, Germany
| | - Holger Stark
- Institute of Pharmaceutical and Medicinal Chemistry, Heinrich Heine University Düsseldorf, Universitätsstraße 1, D-40225, Düsseldorf, Germany
| |
Collapse
|
20
|
Gilmore JL, Sheppeck JE, Watterson SH, Haque L, Mukhopadhyay P, Tebben AJ, Galella MA, Shen DR, Yarde M, Cvijic ME, Borowski V, Gillooly K, Taylor T, McIntyre KW, Warrack B, Levesque PC, Li JP, Cornelius G, D’Arienzo C, Marino A, Balimane P, Salter-Cid L, Barrish JC, Pitts WJ, Carter PH, Xie J, Dyckman AJ. Discovery and Structure–Activity Relationship (SAR) of a Series of Ethanolamine-Based Direct-Acting Agonists of Sphingosine-1-phosphate (S1P1). J Med Chem 2016; 59:6248-64. [DOI: 10.1021/acs.jmedchem.6b00373] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- John L. Gilmore
- Research and Development, Bristol-Myers Squibb,
P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - James E. Sheppeck
- Research and Development, Bristol-Myers Squibb,
P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Scott H. Watterson
- Research and Development, Bristol-Myers Squibb,
P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Lauren Haque
- Research and Development, Bristol-Myers Squibb,
P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Parag Mukhopadhyay
- Research and Development, Bristol-Myers Squibb,
P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Andrew J. Tebben
- Research and Development, Bristol-Myers Squibb,
P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Michael A. Galella
- Research and Development, Bristol-Myers Squibb,
P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Ding Ren Shen
- Research and Development, Bristol-Myers Squibb,
P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Melissa Yarde
- Research and Development, Bristol-Myers Squibb,
P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Mary Ellen Cvijic
- Research and Development, Bristol-Myers Squibb,
P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Virna Borowski
- Research and Development, Bristol-Myers Squibb,
P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Kathleen Gillooly
- Research and Development, Bristol-Myers Squibb,
P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Tracy Taylor
- Research and Development, Bristol-Myers Squibb,
P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Kim W. McIntyre
- Research and Development, Bristol-Myers Squibb,
P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Bethanne Warrack
- Research and Development, Bristol-Myers Squibb,
P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Paul C. Levesque
- Research and Development, Bristol-Myers Squibb,
P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Julia P. Li
- Research and Development, Bristol-Myers Squibb,
P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Georgia Cornelius
- Research and Development, Bristol-Myers Squibb,
P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Celia D’Arienzo
- Research and Development, Bristol-Myers Squibb,
P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Anthony Marino
- Research and Development, Bristol-Myers Squibb,
P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Praveen Balimane
- Research and Development, Bristol-Myers Squibb,
P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Luisa Salter-Cid
- Research and Development, Bristol-Myers Squibb,
P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Joel C. Barrish
- Research and Development, Bristol-Myers Squibb,
P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - William J. Pitts
- Research and Development, Bristol-Myers Squibb,
P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Percy H. Carter
- Research and Development, Bristol-Myers Squibb,
P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Jenny Xie
- Research and Development, Bristol-Myers Squibb,
P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Alaric J. Dyckman
- Research and Development, Bristol-Myers Squibb,
P.O. Box 4000, Princeton, New Jersey 08543, United States
| |
Collapse
|
21
|
Lian Y, Burford K, Londregan AT. Expedient synthesis of gem-dialkylbenzyl heterocycles through olefinic hydroarylation. Tetrahedron 2015. [DOI: 10.1016/j.tet.2015.10.006] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
22
|
New synthetic approach for the preparation of 2-aryl-thiazolo[4,5-b]pyridines via Liebeskind–Srogl reaction. CHINESE CHEM LETT 2015. [DOI: 10.1016/j.cclet.2015.05.012] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
23
|
Urbano M, Guerrero M, Rosen H, Roberts E. Modulators of the Sphingosine 1-phosphate receptor 1. Bioorg Med Chem Lett 2013; 23:6377-89. [PMID: 24125884 DOI: 10.1016/j.bmcl.2013.09.058] [Citation(s) in RCA: 46] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2013] [Revised: 09/17/2013] [Accepted: 09/21/2013] [Indexed: 11/19/2022]
Abstract
The Sphingosine 1-phosphate receptor (S1P-R) signaling system has proven to be of biological and medical importance in autoimmune settings. S1P1-R is a validated drug target for multiple sclerosis (MS) for which FTY720 (Fingolimod), a S1P1,3-5-R pan-agonist, was recently approved as the first orally active drug for the treatment of relapsing-remitting MS. Transient bradycardia and long half-life are the FTY720 critical pitfalls. This review provides the latest advances on next-generation S1P1-R modulators from 2012 up to date, with an overview of the chemical structures, structure-activity relationships, and relevant biological and clinical properties.
Collapse
Affiliation(s)
- Mariangela Urbano
- Department of Chemistry, The Scripps Research Institute, 10550 N. Torrey Pines Rd, La Jolla, CA 92037, United States
| | | | | | | |
Collapse
|
24
|
Banning JE, Gentillon J, Ryabchuk PG, Prosser AR, Rogers A, Edwards A, Holtzen A, Babkov IA, Rubina M, Rubin M. Formal Substitution of Bromocyclopropanes with Nitrogen Nucleophiles. J Org Chem 2013; 78:7601-16. [DOI: 10.1021/jo4011798] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Affiliation(s)
- Joseph E. Banning
- Department of Chemistry, The University
of Kansas, 1251 Wescoe Hall Drive, Lawrence, Kansas 66045-75832
| | - Jacob Gentillon
- Department of Chemistry, The University
of Kansas, 1251 Wescoe Hall Drive, Lawrence, Kansas 66045-75832
| | - Pavel G. Ryabchuk
- Department of Chemistry, The University
of Kansas, 1251 Wescoe Hall Drive, Lawrence, Kansas 66045-75832
| | - Anthony R. Prosser
- Department of Chemistry, The University
of Kansas, 1251 Wescoe Hall Drive, Lawrence, Kansas 66045-75832
| | - Andrew Rogers
- Department of Chemistry, The University
of Kansas, 1251 Wescoe Hall Drive, Lawrence, Kansas 66045-75832
| | - Andrew Edwards
- Department of Chemistry, The University
of Kansas, 1251 Wescoe Hall Drive, Lawrence, Kansas 66045-75832
| | - Andrew Holtzen
- Department of Chemistry, The University
of Kansas, 1251 Wescoe Hall Drive, Lawrence, Kansas 66045-75832
| | - Ivan A. Babkov
- Department of Chemistry, The University
of Kansas, 1251 Wescoe Hall Drive, Lawrence, Kansas 66045-75832
| | - Marina Rubina
- Department of Chemistry, The University
of Kansas, 1251 Wescoe Hall Drive, Lawrence, Kansas 66045-75832
| | - Michael Rubin
- Department of Chemistry, The University
of Kansas, 1251 Wescoe Hall Drive, Lawrence, Kansas 66045-75832
| |
Collapse
|
25
|
Xu H, McElvain M, Fiorino M, Henkle B, Sherman L, Xu Y, Tominey E, Kelley K, Adlam M, Bürli R, Siu J, Wong M, Cee VJ. Predictability of Peripheral Lymphocyte Reduction of Novel S1P1 Agonists by In Vitro GPCR Signaling Profile. ACTA ACUST UNITED AC 2013; 18:997-1007. [DOI: 10.1177/1087057113488629] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Surrogate readouts of G-protein–coupled receptor signaling pathways using highly engineered systems are often employed in the drug discovery process. However, accumulating data have demonstrated the importance of selecting relevant biological activity rather than technically facile assays to support high-throughout screening and subsequent structure-activity relationship studies. Here we report a case study using sphingosine-1-phosphate receptor 1 (S1P1) as the model system to compare compound activity in six different in vitro assays with their ability to predict in vivo efficacy. S1P1 has long been validated as a therapeutic target for autoimmune diseases. In this article, in vivo and in vitro studies on 19 S1P1 agonists are reported. In vitro activities of these S1P1 agonists, together with S1P and FTY720p, on Ca2+ mobilization, adenylyl cyclase inhibition, extracellular signal-related kinase (ERK) phosphorylation, β-arrestin recruitment, and receptor internalization, were determined. The in vitro potency of these compounds was correlated with their ability to induce peripheral lymphocyte reduction. The results revealed that inhibition of adenylyl cyclase and induction of β-arrestin recruitment and receptor internalization are good indicators to predict in vivo efficacy, whereas induction of Ca2+ mobilization through Gqi/5 coupling and ERK phosphorylation is irrelevant. This study demonstrated the importance of identifying an appropriate in vitro assay to predict in vivo activity based on the biological relevance in the drug discovery setting.
Collapse
Affiliation(s)
- Han Xu
- Department of Molecular Structure and Characterization, Amgen, Inc., Thousand Oaks, CA, USA
| | - Michele McElvain
- Department of Molecular Structure and Characterization, Amgen, Inc., Thousand Oaks, CA, USA
| | - Mike Fiorino
- Department of Inflammation Research, Amgen, Inc., Thousand Oaks, CA, USA
| | - Brad Henkle
- Department of Inflammation Research, Amgen, Inc., Thousand Oaks, CA, USA
- Inflammatory Bowel and Immunobiology Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA
| | - Lisa Sherman
- Department of Inflammation Research, Amgen, Inc., Thousand Oaks, CA, USA
| | - Yang Xu
- Department of Pharmacokinetics and Drug Metabolism, Amgen, Inc., Thousand Oaks, CA, USA
| | - Elizabeth Tominey
- Inflammatory Bowel and Immunobiology Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA
- Advanced Pain Care, Austin, TX, USA
| | - Keith Kelley
- Department of Clinical Immunology, Amgen, Inc., Thousand Oaks, CA, USA
| | - Matt Adlam
- Department of Inflammation Research, Amgen, Inc., Thousand Oaks, CA, USA
| | - Roland Bürli
- Department of Medicinal Chemistry Amgen, Inc., Thousand Oaks, CA, USA
- Neuroscience Innovative Medicines, MedImmune AKB, Cambridge, UK
| | - Jerry Siu
- Department of Inflammation Research, Amgen, Inc., Thousand Oaks, CA, USA
- Autoimmune Inflammatory Diseases, Biopharmaceutical Research Unit, Maalov, Denmark
| | - Min Wong
- Department of Inflammation Research, Amgen, Inc., Thousand Oaks, CA, USA
| | - Victor J. Cee
- Department of Medicinal Chemistry Amgen, Inc., Thousand Oaks, CA, USA
| |
Collapse
|
26
|
Zou Y, Qin L, Ren X, Lu Y, Li Y, Zhou J(S. Selective Arylation and Vinylation at the α Position of Vinylarenes. Chemistry 2013; 19:3504-11. [DOI: 10.1002/chem.201203646] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2012] [Indexed: 11/07/2022]
Affiliation(s)
- Yinjun Zou
- Division of Chemistry and Biological Chemistry, School of Physical and Mathematical Sciences, Nanyang Technological University, 21 Nanyang Link, Singapore 637371 (Singapore), Fax: (+65) 67911961
| | - Liena Qin
- Division of Chemistry and Biological Chemistry, School of Physical and Mathematical Sciences, Nanyang Technological University, 21 Nanyang Link, Singapore 637371 (Singapore), Fax: (+65) 67911961
| | - Xinfeng Ren
- Division of Chemistry and Biological Chemistry, School of Physical and Mathematical Sciences, Nanyang Technological University, 21 Nanyang Link, Singapore 637371 (Singapore), Fax: (+65) 67911961
| | - Yunpeng Lu
- Division of Chemistry and Biological Chemistry, School of Physical and Mathematical Sciences, Nanyang Technological University, 21 Nanyang Link, Singapore 637371 (Singapore), Fax: (+65) 67911961
| | - Yongxin Li
- Division of Chemistry and Biological Chemistry, School of Physical and Mathematical Sciences, Nanyang Technological University, 21 Nanyang Link, Singapore 637371 (Singapore), Fax: (+65) 67911961
| | - Jianrong (Steve) Zhou
- Division of Chemistry and Biological Chemistry, School of Physical and Mathematical Sciences, Nanyang Technological University, 21 Nanyang Link, Singapore 637371 (Singapore), Fax: (+65) 67911961
| |
Collapse
|
27
|
Integrating the puzzle pieces: the current atomistic picture of phospholipid-G protein coupled receptor interactions. Biochim Biophys Acta Mol Cell Biol Lipids 2012; 1831:2-12. [PMID: 22982815 DOI: 10.1016/j.bbalip.2012.09.002] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2012] [Revised: 08/31/2012] [Accepted: 09/03/2012] [Indexed: 01/09/2023]
Abstract
A compelling question of how phospholipids interact with their target receptors has been of interest since the first receptor-mediated effects were reported. The recent report of a crystal structure for the S1P(1) receptor in complex with an antagonist phospholipid provides interesting perspective on the insights that had previously been gained through structure-activity studies of the phospholipids, as well as modeling and mutagenesis studies of the receptors. This review integrates these varied lines of investigation in the context of their various contributions to our current understanding of phospholipid-receptor interactions. This article is part of a Special Issue entitled Advances in Lysophospholipid Research.
Collapse
|
28
|
Synthesis and evaluation of CS-2100, a potent, orally active and S1P3- sparing S1P1 agonist. Eur J Med Chem 2012; 51:92-8. [DOI: 10.1016/j.ejmech.2012.02.022] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2011] [Revised: 02/04/2012] [Accepted: 02/13/2012] [Indexed: 11/20/2022]
|
29
|
Deng G, Meng Q, Liu Q, Xu X, Xu Q, Ren F, Guo TB, Lu H, Xiang JN, Elliott JD, Lin X. Identification of benzoxazole analogs as novel, S1P(3) sparing S1P(1) agonists. Bioorg Med Chem Lett 2012; 22:3973-7. [PMID: 22583616 DOI: 10.1016/j.bmcl.2012.04.095] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2012] [Revised: 04/19/2012] [Accepted: 04/20/2012] [Indexed: 10/28/2022]
Abstract
A novel series of benzoxazole-derived S1P(1) agonists were designed based on scaffold hopping molecular design strategy combined with computational approaches. Extensive SAR studies led to the discovery of compound 17d as a selective S1P(1) agonist (over S1P(3)) with high CNS penetration and favorable DMPK properties. 17d also demonstrated in vivo pharmacological efficacy to reduce blood lymphocyte in mice after oral administration.
Collapse
Affiliation(s)
- Guanghui Deng
- Research and Development, GlaxoSmithKline Pharmaceuticals, 898 Halei Road, Zhangjiang Hi-tech Park, Pudong, Shanghai 201023, China
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Asano M, Nakamura T, Sekiguchi Y, Mizuno Y, Yamaguchi T, Tamaki K, Shimozato T, Doi-Komuro H, Kagari T, Tomisato W, Inoue R, Yuita H, Oguchi-Oshima K, Kaneko R, Nara F, Kawase Y, Masubuchi N, Nakayama S, Koga T, Namba E, Nasu H, Nishi T. Synthesis and SAR of 1,3-thiazolyl thiophene and pyridine derivatives as potent, orally active and S1P₃-sparing S1P₁ agonists. Bioorg Med Chem Lett 2012; 22:3083-8. [PMID: 22487179 DOI: 10.1016/j.bmcl.2012.03.067] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2012] [Revised: 03/10/2012] [Accepted: 03/16/2012] [Indexed: 10/28/2022]
Abstract
We have previously disclosed 1,2,4-oxadiazole derivative 3 as a potent S1P(3)-sparing S1P(1) agonist. Although compound 3 exhibits potent and manageable immunosuppressive efficacy in various in vivo models, recent studies have revealed that its 1,2,4-oxadiazole ring is subjected to enterobacterial decomposition. As provisions for unpredictable issues, a series of alternative compounds were synthesized on the basis of compound 3. Extensive SAR studies led to the finding of 1,3-thiazole 24c with the EC(50) value of 3.4 nM for human S1P(1), and over 5800-fold selectivity against S1P(3). In rat on host versus graft reaction (HvGR), the ID(50) value of 24c was determined at 0.07 mg/kg. The pharmacokinetics in rat and monkey is also reported. Compared to compound 3, 24c showed excellent stability against enterobacteria.
Collapse
Affiliation(s)
- Masayoshi Asano
- Lead Discovery & Optimization Research Laboratories I, Daiichi Sankyo Co., Ltd, 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Ryabchuk P, Rubina M, Xu J, Rubin M. Formal Nucleophilic Substitution of Bromocyclopropanes with Azoles. Org Lett 2012; 14:1752-5. [DOI: 10.1021/ol300352z] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Affiliation(s)
- Pavel Ryabchuk
- Department of Chemistry, University of Kansas 1251 Wescoe Hall Drive, Lawrence, Kansas 66045, United States
| | - Marina Rubina
- Department of Chemistry, University of Kansas 1251 Wescoe Hall Drive, Lawrence, Kansas 66045, United States
| | - Jack Xu
- Department of Chemistry, University of Kansas 1251 Wescoe Hall Drive, Lawrence, Kansas 66045, United States
| | - Michael Rubin
- Department of Chemistry, University of Kansas 1251 Wescoe Hall Drive, Lawrence, Kansas 66045, United States
| |
Collapse
|
32
|
Meng Q, Zhao B, Xu Q, Xu X, Deng G, Li C, Luan L, Ren F, Wang H, Xu H, Xu Y, Zhang H, Xiang JN, Elliott JD, Guo TB, Zhao Y, Zhang W, Lu H, Lin X. Indole-propionic acid derivatives as potent, S1P3-sparing and EAE efficacious sphingosine-1-phosphate 1 (S1P1) receptor agonists. Bioorg Med Chem Lett 2012; 22:2794-7. [PMID: 22429468 DOI: 10.1016/j.bmcl.2012.02.083] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2011] [Revised: 02/08/2012] [Accepted: 02/24/2012] [Indexed: 01/12/2023]
Abstract
Novel indole-propionic acid derivatives were developed as sphingosine-1-phosphate (S1P) receptor agonists through a systematic SAR study. The optimized and S1P(3) selective S1P(1) agonist 9f induced peripheral blood lymphocyte reduction in vivo and has an excellent efficacy in mouse experimental autoimmune encephalomyelitis (EAE).
Collapse
Affiliation(s)
- Qinghua Meng
- Research and Development, GlaxoSmithKline Pharmaceuticals, Pudong, Shanghai, China
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Harrington PE, Croghan MD, Fotsch C, Frohn M, Lanman BA, Pennington LD, Pickrell AJ, Reed AB, Sham KKC, Tasker A, Arnett HA, Fiorino M, Lee MR, McElvain M, Morrison HG, Xu H, Xu Y, Zhang X, Wong M, Cee VJ. Optimization of a Potent, Orally Active S1P1 Agonist Containing a Quinolinone Core. ACS Med Chem Lett 2012; 3:74-8. [PMID: 24900374 DOI: 10.1021/ml200252b] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2011] [Accepted: 11/23/2011] [Indexed: 01/18/2023] Open
Abstract
The optimization of a series of S1P1 agonists with limited activity against S1P3 is reported. A polar headgroup was used to improve the physicochemical and pharmacokinetic parameters of lead quinolinone 6. When dosed orally at 1 and 3 mg/kg, the azahydroxymethyl analogue 22 achieved statistically significant lowering of circulating blood lymphocytes 24 h postdose. In rats, a dose-proportional increase in exposure was measured when 22 was dosed orally at 2 and 100 mg/kg.
Collapse
Affiliation(s)
- Paul E. Harrington
- Chemistry
Research and Discovery, ‡Inflammation Research, §Molecular Structure, ∥HTS and Molecular Pharmacology, ⊥Pharmaceutics, and #Pharmacokinetics and
Drug Metabolism, Amgen, One
Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
| | - Michael D. Croghan
- Chemistry
Research and Discovery, ‡Inflammation Research, §Molecular Structure, ∥HTS and Molecular Pharmacology, ⊥Pharmaceutics, and #Pharmacokinetics and
Drug Metabolism, Amgen, One
Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
| | - Christopher Fotsch
- Chemistry
Research and Discovery, ‡Inflammation Research, §Molecular Structure, ∥HTS and Molecular Pharmacology, ⊥Pharmaceutics, and #Pharmacokinetics and
Drug Metabolism, Amgen, One
Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
| | - Mike Frohn
- Chemistry
Research and Discovery, ‡Inflammation Research, §Molecular Structure, ∥HTS and Molecular Pharmacology, ⊥Pharmaceutics, and #Pharmacokinetics and
Drug Metabolism, Amgen, One
Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
| | - Brian A. Lanman
- Chemistry
Research and Discovery, ‡Inflammation Research, §Molecular Structure, ∥HTS and Molecular Pharmacology, ⊥Pharmaceutics, and #Pharmacokinetics and
Drug Metabolism, Amgen, One
Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
| | - Lewis D. Pennington
- Chemistry
Research and Discovery, ‡Inflammation Research, §Molecular Structure, ∥HTS and Molecular Pharmacology, ⊥Pharmaceutics, and #Pharmacokinetics and
Drug Metabolism, Amgen, One
Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
| | - Alexander J. Pickrell
- Chemistry
Research and Discovery, ‡Inflammation Research, §Molecular Structure, ∥HTS and Molecular Pharmacology, ⊥Pharmaceutics, and #Pharmacokinetics and
Drug Metabolism, Amgen, One
Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
| | - Anthony B. Reed
- Chemistry
Research and Discovery, ‡Inflammation Research, §Molecular Structure, ∥HTS and Molecular Pharmacology, ⊥Pharmaceutics, and #Pharmacokinetics and
Drug Metabolism, Amgen, One
Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
| | - Kelvin K. C. Sham
- Chemistry
Research and Discovery, ‡Inflammation Research, §Molecular Structure, ∥HTS and Molecular Pharmacology, ⊥Pharmaceutics, and #Pharmacokinetics and
Drug Metabolism, Amgen, One
Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
| | - Andrew Tasker
- Chemistry
Research and Discovery, ‡Inflammation Research, §Molecular Structure, ∥HTS and Molecular Pharmacology, ⊥Pharmaceutics, and #Pharmacokinetics and
Drug Metabolism, Amgen, One
Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
| | - Heather A. Arnett
- Chemistry
Research and Discovery, ‡Inflammation Research, §Molecular Structure, ∥HTS and Molecular Pharmacology, ⊥Pharmaceutics, and #Pharmacokinetics and
Drug Metabolism, Amgen, One
Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
| | - Michael Fiorino
- Chemistry
Research and Discovery, ‡Inflammation Research, §Molecular Structure, ∥HTS and Molecular Pharmacology, ⊥Pharmaceutics, and #Pharmacokinetics and
Drug Metabolism, Amgen, One
Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
| | - Matthew R. Lee
- Chemistry
Research and Discovery, ‡Inflammation Research, §Molecular Structure, ∥HTS and Molecular Pharmacology, ⊥Pharmaceutics, and #Pharmacokinetics and
Drug Metabolism, Amgen, One
Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
| | - Michele McElvain
- Chemistry
Research and Discovery, ‡Inflammation Research, §Molecular Structure, ∥HTS and Molecular Pharmacology, ⊥Pharmaceutics, and #Pharmacokinetics and
Drug Metabolism, Amgen, One
Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
| | - Henry G. Morrison
- Chemistry
Research and Discovery, ‡Inflammation Research, §Molecular Structure, ∥HTS and Molecular Pharmacology, ⊥Pharmaceutics, and #Pharmacokinetics and
Drug Metabolism, Amgen, One
Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
| | - Han Xu
- Chemistry
Research and Discovery, ‡Inflammation Research, §Molecular Structure, ∥HTS and Molecular Pharmacology, ⊥Pharmaceutics, and #Pharmacokinetics and
Drug Metabolism, Amgen, One
Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
| | - Yang Xu
- Chemistry
Research and Discovery, ‡Inflammation Research, §Molecular Structure, ∥HTS and Molecular Pharmacology, ⊥Pharmaceutics, and #Pharmacokinetics and
Drug Metabolism, Amgen, One
Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
| | - Xuxia Zhang
- Chemistry
Research and Discovery, ‡Inflammation Research, §Molecular Structure, ∥HTS and Molecular Pharmacology, ⊥Pharmaceutics, and #Pharmacokinetics and
Drug Metabolism, Amgen, One
Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
| | - Min Wong
- Chemistry
Research and Discovery, ‡Inflammation Research, §Molecular Structure, ∥HTS and Molecular Pharmacology, ⊥Pharmaceutics, and #Pharmacokinetics and
Drug Metabolism, Amgen, One
Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
| | - Victor J. Cee
- Chemistry
Research and Discovery, ‡Inflammation Research, §Molecular Structure, ∥HTS and Molecular Pharmacology, ⊥Pharmaceutics, and #Pharmacokinetics and
Drug Metabolism, Amgen, One
Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
| |
Collapse
|
34
|
Nakamura T, Asano M, Sekiguchi Y, Mizuno Y, Tamaki K, Kimura T, Nara F, Kawase Y, Shimozato T, Doi H, Kagari T, Tomisato W, Inoue R, Nagasaki M, Yuita H, Oguchi-Oshima K, Kaneko R, Watanabe N, Abe Y, Nishi T. Discovery of CS-2100, a potent, orally active and S1P3-sparing S1P1 agonist. Bioorg Med Chem Lett 2012; 22:1788-92. [PMID: 22264485 DOI: 10.1016/j.bmcl.2011.12.019] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2011] [Revised: 11/25/2011] [Accepted: 12/03/2011] [Indexed: 10/14/2022]
Abstract
S1P(3)-sparing S1P(1) agonists have attracted attention as a suppressant of autoimmunity with reduced side effects. Our synthetic efforts and extensive SAR studies led to the discovery of 10b named CS-2100 with the EC(50) value of 4.0 nM for human S1P(1) and over 5000-fold selectivity against S1P(3). The in vivo immunosuppressive efficacy was evaluated in rats on host versus graft reaction and the ID(50) value was determined at 0.407mg/kg. The docking studies of CS-2100 with the homology model of S1P(1) and S1P(3) showed that the ethyl group on the thiophene ring of CS-2100 was sterically hindered by Phe263 in S1P(3), not in the case of Leu276 in S1P(1). This observation gives an explanation for the excellent S1P(3)-sparing characteristic of CS-2100.
Collapse
Affiliation(s)
- Tsuyoshi Nakamura
- Lead Discovery & Optimization Research Laboratories I, Daiichi Sankyo Co., Ltd, Shinagawa-ku, Tokyo, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Recent Advances in the Discovery and Development of Sphingosine-1-Phosphate-1 Receptor Agonists. ANNUAL REPORTS IN MEDICINAL CHEMISTRY 2012. [DOI: 10.1016/b978-0-12-396492-2.00013-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 04/09/2023]
|
36
|
Reed AB, Lanman BA, Neira S, Harrington PE, Sham KKC, Frohn M, Pickrell AJ, Tasker AS, Gore A, Fiorino M, Itano A, McElvain M, Middleton S, Morrison H, Xu H, Xu Y, Wong M, Cee VJ. Isoform-selective thiazolo[5,4-b]pyridine S1P1 agonists possessing acyclic amino carboxylate head-groups. Bioorg Med Chem Lett 2011; 22:1779-83. [PMID: 22257889 DOI: 10.1016/j.bmcl.2011.12.073] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2011] [Revised: 12/06/2011] [Accepted: 12/08/2011] [Indexed: 11/27/2022]
Abstract
Replacement of the azetidine carboxylate of an S1P(1) agonist development candidate, AMG 369, with a range of acyclic head-groups led to the identification of a novel, S1P(3)-sparing S1P(1) agonist, (-)-2-amino-4-(3-fluoro-4-(5-(1-phenylcyclopropyl)thiazolo[5,4-b]pyridin-2-yl)phenyl)-2-methylbutanoic acid (8c), which possessed good in vivo efficacy and pharmacokinetic properties. A 0.3mg/kg oral dose of 8c produced a statistically significant reduction in blood lymphocyte counts 24h post-dosing in female Lewis rats.
Collapse
Affiliation(s)
- Anthony B Reed
- Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91320, United States.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Quinolinone-based agonists of S1P₁: use of a N-scan SAR strategy to optimize in vitro and in vivo activity. Bioorg Med Chem Lett 2011; 22:527-31. [PMID: 22104144 DOI: 10.1016/j.bmcl.2011.10.085] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2011] [Revised: 10/24/2011] [Accepted: 10/26/2011] [Indexed: 02/03/2023]
Abstract
We reveal how a N-scan SAR strategy (systematic substitution of each CH group with a N atom) was employed for quinolinone-based S1P(1) agonist 5 to modulate physicochemical properties and optimize in vitro and in vivo activity. The diaza-analog 17 displays improved potency (hS1P(1) RI; 17: EC(50)=0.020 μM, 120% efficacy; 5: EC(50)=0.070 μM, 110% efficacy) and selectivity (hS1P(3) Ca(2+) flux; 17: EC(50) >25 μM; 5: EC(50)=1.5 μM, 92% efficacy), as well as enhanced pharmacokinetics (17: CL=0.15 L/h/kg, V(dss)=5.1L/kg, T(1/2)=24h, %F=110; 5: CL=0.93L/h/kg, V(dss)=11L/kg, T(1/2)=15 h, %F=60) and pharmacodynamics (17: 1.0mg/kg po, 24h PLC POC=-67%; 5: 3mg/kg po, 24h PLC POC=-51%) in rat.
Collapse
|
38
|
Frohn M, Cee VJ, Lanman BA, Pickrell AJ, Golden J, Rivenzon-Segal D, Middleton S, Fiorino M, Xu H, Schrag M, Xu Y, McElvain M, Muller K, Siu J, Bürli R. Novel 5- and 6-subtituted benzothiazoles with improved physicochemical properties: potent S1P₁ agonists with in vivo lymphocyte-depleting activity. Bioorg Med Chem Lett 2011; 22:628-33. [PMID: 22100314 DOI: 10.1016/j.bmcl.2011.10.069] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2011] [Revised: 10/18/2011] [Accepted: 10/20/2011] [Indexed: 11/18/2022]
Abstract
An SAR campaign designed to increase polarity in the 'tail' region of benzothiazole 1 resulted in two series of structurally novel 5-and 6-substituted S1P(1) agonists. Structural optimization for potency ultimately delivered carboxamide (+)-11f, which in addition to possessing improved physicochemical properties relative to starting benzothiazole 1, also displayed good S1P(3) selectivity and acceptable in vivo lymphocyte-depleting activity.
Collapse
Affiliation(s)
- Mike Frohn
- Department of Medicinal Chemistry, Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91320, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Pennington LD, Sham KKC, Pickrell AJ, Harrington PE, Frohn MJ, Lanman BA, Reed AB, Croghan MD, Lee MR, Xu H, McElvain M, Xu Y, Zhang X, Fiorino M, Horner M, Morrison HG, Arnett HA, Fotsch C, Wong M, Cee VJ. 4-Methoxy-N-[2-(trifluoromethyl)biphenyl-4-ylcarbamoyl]nicotinamide: A Potent and Selective Agonist of S1P1. ACS Med Chem Lett 2011; 2:752-7. [PMID: 24900263 DOI: 10.1021/ml2001399] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2011] [Accepted: 07/29/2011] [Indexed: 01/06/2023] Open
Abstract
The sphingosine-1-phosphate-1 receptor (S1P1) and its endogenous ligand sphingosine-1-phosphate (S1P) cooperatively regulate lymphocyte trafficking from the lymphatic system. Herein, we disclose 4-methoxy-N-[2-(trifluoromethyl)biphenyl-4-ylcarbamoyl]nicotinamide (8), an uncommon example of a synthetic S1P1 agonist lacking a polar headgroup, which is shown to effect dramatic reduction of circulating lymphocytes (POC = -78%) in rat 24 h after a single oral dose (1 mg/kg). The excellent potency that 8 exhibits toward S1P1 (EC50 = 0.035 μM, 96% efficacy) and the >100-fold selectivity that it displays against receptor subtypes S1P2-5 suggest that it may serve as a valuable tool to understand the clinical relevance of selective S1P1 agonism.
Collapse
Affiliation(s)
- Lewis D. Pennington
- Medicinal Chemistry, ‡Molecular Structure, §HTS and Molecular Pharmacology, ∥Inflammation Research, ⊥Pharmacokinetics and Drug Metabolism, #Toxicology, and +Pharmaceutics, Amgen, One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
| | - Kelvin K. C. Sham
- Medicinal Chemistry, ‡Molecular Structure, §HTS and Molecular Pharmacology, ∥Inflammation Research, ⊥Pharmacokinetics and Drug Metabolism, #Toxicology, and +Pharmaceutics, Amgen, One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
| | - Alexander J. Pickrell
- Medicinal Chemistry, ‡Molecular Structure, §HTS and Molecular Pharmacology, ∥Inflammation Research, ⊥Pharmacokinetics and Drug Metabolism, #Toxicology, and +Pharmaceutics, Amgen, One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
| | - Paul E. Harrington
- Medicinal Chemistry, ‡Molecular Structure, §HTS and Molecular Pharmacology, ∥Inflammation Research, ⊥Pharmacokinetics and Drug Metabolism, #Toxicology, and +Pharmaceutics, Amgen, One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
| | - Michael J. Frohn
- Medicinal Chemistry, ‡Molecular Structure, §HTS and Molecular Pharmacology, ∥Inflammation Research, ⊥Pharmacokinetics and Drug Metabolism, #Toxicology, and +Pharmaceutics, Amgen, One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
| | - Brian A. Lanman
- Medicinal Chemistry, ‡Molecular Structure, §HTS and Molecular Pharmacology, ∥Inflammation Research, ⊥Pharmacokinetics and Drug Metabolism, #Toxicology, and +Pharmaceutics, Amgen, One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
| | - Anthony B. Reed
- Medicinal Chemistry, ‡Molecular Structure, §HTS and Molecular Pharmacology, ∥Inflammation Research, ⊥Pharmacokinetics and Drug Metabolism, #Toxicology, and +Pharmaceutics, Amgen, One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
| | - Michael D. Croghan
- Medicinal Chemistry, ‡Molecular Structure, §HTS and Molecular Pharmacology, ∥Inflammation Research, ⊥Pharmacokinetics and Drug Metabolism, #Toxicology, and +Pharmaceutics, Amgen, One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
| | - Matthew R. Lee
- Medicinal Chemistry, ‡Molecular Structure, §HTS and Molecular Pharmacology, ∥Inflammation Research, ⊥Pharmacokinetics and Drug Metabolism, #Toxicology, and +Pharmaceutics, Amgen, One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
| | - Han Xu
- Medicinal Chemistry, ‡Molecular Structure, §HTS and Molecular Pharmacology, ∥Inflammation Research, ⊥Pharmacokinetics and Drug Metabolism, #Toxicology, and +Pharmaceutics, Amgen, One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
| | - Michele McElvain
- Medicinal Chemistry, ‡Molecular Structure, §HTS and Molecular Pharmacology, ∥Inflammation Research, ⊥Pharmacokinetics and Drug Metabolism, #Toxicology, and +Pharmaceutics, Amgen, One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
| | - Yang Xu
- Medicinal Chemistry, ‡Molecular Structure, §HTS and Molecular Pharmacology, ∥Inflammation Research, ⊥Pharmacokinetics and Drug Metabolism, #Toxicology, and +Pharmaceutics, Amgen, One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
| | - Xuxia Zhang
- Medicinal Chemistry, ‡Molecular Structure, §HTS and Molecular Pharmacology, ∥Inflammation Research, ⊥Pharmacokinetics and Drug Metabolism, #Toxicology, and +Pharmaceutics, Amgen, One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
| | - Michael Fiorino
- Medicinal Chemistry, ‡Molecular Structure, §HTS and Molecular Pharmacology, ∥Inflammation Research, ⊥Pharmacokinetics and Drug Metabolism, #Toxicology, and +Pharmaceutics, Amgen, One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
| | - Michelle Horner
- Medicinal Chemistry, ‡Molecular Structure, §HTS and Molecular Pharmacology, ∥Inflammation Research, ⊥Pharmacokinetics and Drug Metabolism, #Toxicology, and +Pharmaceutics, Amgen, One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
| | - Henry G. Morrison
- Medicinal Chemistry, ‡Molecular Structure, §HTS and Molecular Pharmacology, ∥Inflammation Research, ⊥Pharmacokinetics and Drug Metabolism, #Toxicology, and +Pharmaceutics, Amgen, One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
| | - Heather A. Arnett
- Medicinal Chemistry, ‡Molecular Structure, §HTS and Molecular Pharmacology, ∥Inflammation Research, ⊥Pharmacokinetics and Drug Metabolism, #Toxicology, and +Pharmaceutics, Amgen, One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
| | - Christopher Fotsch
- Medicinal Chemistry, ‡Molecular Structure, §HTS and Molecular Pharmacology, ∥Inflammation Research, ⊥Pharmacokinetics and Drug Metabolism, #Toxicology, and +Pharmaceutics, Amgen, One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
| | - Min Wong
- Medicinal Chemistry, ‡Molecular Structure, §HTS and Molecular Pharmacology, ∥Inflammation Research, ⊥Pharmacokinetics and Drug Metabolism, #Toxicology, and +Pharmaceutics, Amgen, One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
| | - Victor J. Cee
- Medicinal Chemistry, ‡Molecular Structure, §HTS and Molecular Pharmacology, ∥Inflammation Research, ⊥Pharmacokinetics and Drug Metabolism, #Toxicology, and +Pharmaceutics, Amgen, One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
| |
Collapse
|
40
|
Demont EH, Arpino S, Bit RA, Campbell CA, Deeks N, Desai S, Dowell SJ, Gaskin P, Gray JRJ, Harrison LA, Haynes A, Heightman TD, Holmes DS, Humphreys PG, Kumar U, Morse MA, Osborne GJ, Panchal T, Philpott KL, Taylor S, Watson R, Willis R, Witherington J. Discovery of a brain-penetrant S1P₃-sparing direct agonist of the S1P₁ and S1P₅ receptors efficacious at low oral dose. J Med Chem 2011; 54:6724-33. [PMID: 21838322 DOI: 10.1021/jm200609t] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
2-Amino-2-(4-octylphenethyl)propane-1,3-diol 1 (fingolimod, FTY720) has been recently marketed in the United States for the treatment of patients with remitting relapsing multiple sclerosis (RRMS). Its efficacy has been primarily linked to the agonism on T cells of S1P(1), one of the five sphingosine 1-phosphate (S1P) G-protein-coupled receptors, while its cardiovascular side effects have been associated with activity at S1P(3). Emerging data suggest that the ability of this molecule to cross the blood-brain barrier and to interact with both S1P(1) and S1P(5) in the central nervous system (CNS) may contribute to its efficacy in treating patients with RRMS. We have recently disclosed the structure of an advanced, first generation S1P(3)-sparing S1P(1) agonist, a zwitterion with limited CNS exposure. In this Article, we highlight our strategy toward the identification of CNS-penetrant S1P(3)-sparing S1P(1) and S1P(5) agonists resulting in the discovery of 5-(3-{2-[2-hydroxy-1-(hydroxymethyl)ethyl]-5-methyl-1,2,3,4-tetrahydro-6-isoquinolinyl}-1,2,4-oxadiazol-5-yl)-2-[(1-methylethyl)oxy]benzonitrile 15. Its exceptional in vivo potency and good pharmacokinetic properties translate into a very low predicted therapeutic dose in human (<1 mg p.o. once daily).
Collapse
Affiliation(s)
- Emmanuel H Demont
- Immuno Inflammation Center of Excellence for Drug Discovery, GlaxoSmithKline, Gunnels Wood Road, Stevenage SG1 2NY, United Kingdom.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Morrison H, Burke B, Lei D, Robertson V, Nagapudi K, Chan J, Gore A, Fang J, Jona J. Development of a Suitable Physical Form for a Sphingosine-1-phosphate Receptor Agonist. Org Process Res Dev 2011. [DOI: 10.1021/op200192n] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Henry Morrison
- Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Brenda Burke
- Gilead Inc., 333 Lakeside Dr, Foster City, California 94404, United States
| | - Dennis Lei
- Allergan Inc., 2525 Dupont Drive, Irvine, California 92612, United States
| | - Vivian Robertson
- Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Karthik Nagapudi
- Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Johann Chan
- Gilead Inc., 333 Lakeside Dr, Foster City, California 94404, United States
| | - Anu Gore
- Allergan Inc., 2525 Dupont Drive, Irvine, California 92612, United States
| | - Jan Fang
- Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Jonan Jona
- Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| |
Collapse
|